Compugen Ltd. (CGEN)

Market Cap	135.59M
Revenue (ttm)	27.86M
Net Income (ttm)	-14.23M
Shares Out	93.51M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,281
Open	1.420
Previous Close	1.390
Day's Range	1.385 - 1.465
52-Week Range	1.130 - 2.660
Beta	3.20
Analysts	Strong Buy
Price Target	4.00 (+175.86%)
Earnings Date	May 19, 2025

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/T...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2000
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: CGEN
• Website: https://cgen.com

Financial Performance

In 2024, Compugen's revenue was $27.86 million, a decrease of -16.72% compared to the previous year's $33.46 million. Losses were -$14.23 million, -24.12% less than in 2023.

Analyst Forecast

According to one analyst, the rating for CGEN stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(175.86% upside)

Analyst Consensus: Strong Buy